Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells $195,350.00 in Stock

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) insider Dana Pizzuti sold 5,000 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $39.07, for a total transaction of $195,350.00. Following the completion of the sale, the insider now directly owns 31,748 shares in the company, valued at $1,240,394.36. This trade represents a 13.61 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Crinetics Pharmaceuticals Stock Down 2.7 %

NASDAQ CRNX traded down $1.10 on Wednesday, hitting $39.30. 614,538 shares of the stock were exchanged, compared to its average volume of 1,100,311. Crinetics Pharmaceuticals, Inc. has a fifty-two week low of $35.51 and a fifty-two week high of $62.53. The company has a market cap of $3.64 billion, a PE ratio of -10.54 and a beta of 0.56. The company has a 50-day moving average price of $48.56 and a 200-day moving average price of $52.07.

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts' consensus estimates of ($0.91) by ($0.05). During the same period last year, the firm posted ($1.01) EPS. As a group, equities research analysts predict that Crinetics Pharmaceuticals, Inc. will post -3.73 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on CRNX. HC Wainwright restated a "buy" rating and set a $81.00 target price on shares of Crinetics Pharmaceuticals in a report on Monday, January 13th. Jefferies Financial Group raised shares of Crinetics Pharmaceuticals from a "hold" rating to a "buy" rating and set a $55.00 price target for the company in a report on Wednesday, January 22nd. JMP Securities reaffirmed a "market outperform" rating and issued a $87.00 price objective on shares of Crinetics Pharmaceuticals in a research note on Monday, December 16th. Wolfe Research initiated coverage on Crinetics Pharmaceuticals in a research report on Tuesday. They set a "peer perform" rating on the stock. Finally, Citigroup increased their price objective on Crinetics Pharmaceuticals from $70.00 to $74.00 and gave the stock a "buy" rating in a research note on Thursday, November 14th. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $72.64.

Institutional Investors Weigh In On Crinetics Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Venturi Wealth Management LLC acquired a new position in shares of Crinetics Pharmaceuticals in the fourth quarter worth $41,000. Values First Advisors Inc. acquired a new stake in shares of Crinetics Pharmaceuticals in the third quarter valued at $84,000. Allspring Global Investments Holdings LLC bought a new position in Crinetics Pharmaceuticals in the third quarter valued at about $91,000. KBC Group NV boosted its holdings in Crinetics Pharmaceuticals by 22.8% during the third quarter. KBC Group NV now owns 2,193 shares of the company's stock worth $112,000 after buying an additional 407 shares during the last quarter. Finally, Advisors Asset Management Inc. raised its position in shares of Crinetics Pharmaceuticals by 56.1% during the third quarter. Advisors Asset Management Inc. now owns 2,806 shares of the company's stock worth $143,000 after purchasing an additional 1,008 shares during the period. 98.51% of the stock is currently owned by institutional investors and hedge funds.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.